Skip to main content
. 2020 Oct 13;8(10):411. doi: 10.3390/biomedicines8100411

Figure 7.

Figure 7

(A) Representative phase-contrast micrographs of HEMn-DP cells of Ctrl (0.4% DMSO) and CMT-308 (10 µM)-treated groups; quantification of melanocyte dendricity by (B) total dendrite length; (C) number of dendrites; (D) % cells with >2 dendrites; # p < 0.01 vs. Ctrl; (E) representative phase-contrast micrographs of HEMn-DP cells showing exposure and recovery of Ctrl and CMT-308-treated groups; quantification of dendricity by (F) total dendrite length; (G) number of dendrites; and (H) % cells with >2 dendrites; # p < 0.01 vs. Ctrl; data is mean ± SD of one representative experiment in triplicates with a total of 50–60 cells counted per group.